List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 24 studies with search of: "Rifaximin"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Induction of Clinical Response Using Rifaximin in Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Placebo Comparator;   Drug: Rifaximin
2 Recruiting RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
Condition: Hepatic Encephalopathy
Intervention: Drug: Rifaximin alone, Rifaximin combined with Lactulose
3 Active, not recruiting Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: Rifaximin-EIR
4 Completed Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea
Condition: Diarrhea
Intervention: Drug: rifaximin
5 Active, not recruiting Rifaximin 3 Times/Day for Non-Constipation IBS
Condition: Non-Constipation Irritable Bowel Syndrome
Interventions: Drug: Rifaximin;   Drug: Placebo
6 Active, not recruiting Rifaximin TID for Non-Constipation Irritable Bowel Syndrome (IBS)
Condition: Non-Constipation Irritable Bowel Syndrome
Interventions: Drug: Rifaximin;   Drug: Placebo
7 Not yet recruiting Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea
Condition: Travelers' Diarrhea
Intervention: Drug: Rifaximin
8 Completed Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers
Condition: Pharmacokinetic
Intervention: Drug: rifaximin
9 Completed Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea
Condition: Travelers' Diarrhea
Intervention: Drug: Rifaximin and loperamide
10 Completed A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Conditions: Clostridium Infections;   Diarrhea
Intervention: Drug: Rifaximin (Xifaxan)
11 Recruiting Rifaximin in Minimal Hepatic Encephalopathy
Condition: Hepatic Encephalopathy
Interventions: Drug: Rifaximin;   Drug: placebo
12 Recruiting The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Hepatitis C;   Liver Cirrhosis
Intervention: Drug: Rifaximin (drug)
13 Completed Rifaximin for the Treatment of Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome
Intervention: Drug: Rifaximin
14 Recruiting Rifaximin Versus Lactulose in Renal Failure
Conditions: Liver Cirrhosis;   Renal Failure
Interventions: Drug: Rifaximin;   Drug: Lactulose
15 Completed Rifaximin for Prevention of Travellers' Diarrhea
Condition: Diarrhea
Interventions: Drug: Rifaximin;   Drug: Placebo
16 Completed Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
Condition: Diarrhea
Intervention: Drug: Rifaximin
17 Completed Trial of Rifaximin in the Treatment of Tropical Enteropathy
Condition: Tropical Enteropathy
Intervention: Drug: Rifaximin
18 Active, not recruiting A 6-Month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
Condition: Hepatic Encephalopathy
Intervention: Drug: Rifaximin
19 Completed Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome
Intervention: Drug: Rifaximin
20 Enrolling by invitation Transit Time and Bacterial Overgrowth Using SmartPill Capsule
Conditions: Small Bowel Bacterial Overgrowth;   Gastrointestinal Diseases;   Stomach Diseases;   Digestive System Diseases
Intervention: Drug: Xifaxan

Previous Page Studies Shown (1-20) Next Page (21-24)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services